IBA to Equip Portugal's First Proton Therapy Center in Porto
IBA has announced that its contract signed in April with the Portuguese Institute of Oncology of Porto (IPO-Porto) has come into effect following approval by the Portuguese regulatory authority. Two compact Proteus One systems will be installed, establishing the country's first proton therapy center.
Two Proteus One Systems for Portugal, the First National Center
The Portuguese Institute of Oncology of Porto (IPO-Porto) will host two compact Proteus One solutions in a side-by-side configuration, designed to maximize clinical availability, operational flexibility, and therapeutic efficiency. These systems will form the National Proton Therapy Center of Portugal, the country's first proton therapy center. Signed in April, the contract became effective on Tuesday after mandatory review by the Portuguese Court of Auditors. The agreement resulted from a public tender launched in November 2025 and awarded to IBA. It followed a prior agreement between the Amancio Ortega Gaona Foundation (FAO), the Portuguese Ministry of Health, the Ministry of Territorial Cohesion, and IPO-Porto.
Maintenance Services and Commissioning in 2029
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The contract includes a period of operational and maintenance services provided by IBA. IPO-Porto plans to begin patient treatments in 2029. The typical price for a Proteus One system, including a multi-year maintenance contract, ranges between 35 and 45 million euros.
A Signal for Access to Proton Therapy in Europe
This order is part of an accelerated dynamic of IBA's expansion in proton therapy. The group won a contract on June 8 for two Proteus One systems at the Duke Proton Center in North Carolina, and on June 25, signed an agreement with the Fundação Severino Sombra in Brazil to establish the first national proton therapy center in Brazil. Olivier Legrain, CEO of IBA, stated, 'In line with our mission to make innovative proton therapy solutions accessible to more patients, we are proud to have been selected to install the first proton therapy center in Portugal.' Dr. Julio Oliveira, chairman of the board of IPO-Porto, emphasized, 'The awarding of this equipment makes the National Proton Therapy Center irreversible. For years, we have worked towards a single goal: to finally offer Portugal the ability to provide its patients, including children, with this high-precision treatment that currently forces them to travel abroad.'
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
